Top Suppliers:I want be here

59-33-6

59-33-6 structure
59-33-6 structure
  • Name: Pyrilamine Maleate Salt
  • Chemical Name: Pyrilamine Maleate Salt
  • CAS Number: 59-33-6
  • Molecular Formula: C21H27N3O5
  • Molecular Weight: 401.45600
  • Catalog: API Antiallergic Antihistamine
  • Create Date: 2018-08-08 12:54:56
  • Modify Date: 2024-01-03 01:52:37
  • Mepyramine maleate, a first generation antihistamine, is an antagonist of histamine H1 receptor, with Kds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a pKd of 9.4 for H1 receptor.

Name Pyrilamine Maleate Salt
Synonyms EINECS 200-422-7
pyrilamine maleate
MFCD00069333
Mepyramine maleate
Description Mepyramine maleate, a first generation antihistamine, is an antagonist of histamine H1 receptor, with Kds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a pKd of 9.4 for H1 receptor.
Related Catalog
Target

Kd: 0.8 nM (Histamine H1 receptor), 5200 nM (Histamine H2 receptor), >3000 nM (Histamine H3 receptor)[1] pKd: 9.4 (Histamine H1 receptor)[2]

In Vitro Mepyramine maleate is an antagonist of histamine H1 receptor, with Kds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively[1], and a pKd of 9.4 for H1 receptor[2]. Mepyramine binds to the H1 receptor with different Kds in Guinea pig brain (0.8 nM), rat brain (9.1 nM) and DDT1-MF-2 and BC3H1 cell (276 nM)[1]. Mepyramine decreases the InsP levels in CHO-gpH1 cells, with log EC50 of -7.94 ± 0.11, and reduces the the maximal response to ATP in CHO-gpH1 cells[3].
In Vivo Mepyramine obviously decreases the second phase of nociceptive response via i.p at 10 and 20 mg/kg, but shows no significant effect at 5 mg/kg in rats[4].
Cell Assay Briefly, cells are seeded in 24-well cluster dishes and cultured for 24 h (70-80% confluence) in DMEM. Cells are then washed, and the medium is replaced for DMEM without calf serum plus the addition of myo-[3H]inositol (2 μCi/mL) and cultured for 24 h. Thereafter, the medium is aspirated and replaced with DMEM without calf serum containing 10 mM LiCl and incubated for 20 min. Cells are then stimulated for 20 min with histamine in concentrations ranging from 1 nM to 100 μM in a final volume of 300 μL in the presence or absence of [3H]inositol the concentrations indicated in each particular experiment. The incubation is stopped by the addition of 900 μL of cold chloroform, methanol, 0.12 M HCl (1:2:1 v/v, freshly prepared), and phases are split by the addition of 300 μL of water and 300 μL of chloroform. The mixture is then centrifuged at 1500 × g for 10 min, and the total water-soluble inositol phosphate fraction is purified by anion exchange chromatography. Radioactivity of the eluted fractions is measured using a liquid scintillation counter. Results are expressed as the ratio obtained when total [3H]inositol phosphate radioactivity is normalized to total [3H]inositol radioactivity recovered from the initial water wash of the columns[3].
Animal Admin Rats[4] Healthy adult male albino Wistar rats weighing 200-220 g are maintained in polypropylene cages with 6 rats in each cage with food and water available ad libitum. Mepyramine is dissolved in normal saine. Mepyramine at doses of 5, 10, and 20 mg/kg and intraperitoneally injected 30 min before induction of nociception. Physostigmine at doses of 0.05, 0.1, and 0.2 mg/kg, and atropine at a dose of 2 mg/kg, are subcutaneously administered 20 and 40 min before induction of formalin-induced pain, respectively. Atropine (2 mg/kg, s.c.) is injected 20 min before subcutaneous injection of physostigmine (0.1 mg/kg). In combined treatment, intraperitoneal injections of mepyramine (10 mg/kg) and famotidine (20 mg/kg) are performed 10 min before physostigmine (0.1 mg/kg, s.c.) and 10 min after atropine (0.2 mg/kg, s.c.) administrations. Drug solutions are intraperitoneally injected in a volum of 1 mL/kg, using a 25-gauge injection needle. Subcutaneous injections of drug solutions are perfoemed in a constant volume 0.2 mL per rat at the neck region using a 27-gauge injection needle[4].
References

[1]. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev. 1990 Mar;42(1):45-83.

[2]. van der Goot H1, et al. Selective ligands as tools to study histamine receptors. Eur J Med Chem. 2000 Jan;35(1):5-20.

[3]. Fitzsimons CP, et al. Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein. J Biol Chem. 2004 Aug 13;279(33):34431-9.

[4]. Mojtahedin A, et al. Effects of mepyramine and famotidine on the physostigmine-induced antinociception in the formalin test in rats. Pak J Biol Sci. 2008 Nov 15;11(22):2573-8.

Boiling Point 423.8ºC at 760 mmHg
Melting Point 100-101ºC
Molecular Formula C21H27N3O5
Molecular Weight 401.45600
Flash Point 210.1ºC
Exact Mass 401.19500
PSA 103.20000
LogP 2.37020
Storage condition 2-8°C
Stability Stability Combustible. Incompatible with strong oxidizing agents.

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UT1225000
CAS REGISTRY NUMBER :
59-33-6
LAST UPDATED :
199701
DATA ITEMS CITED :
24
MOLECULAR FORMULA :
C17-H23-N3-O.C4-H4-O4
MOLECULAR WEIGHT :
401.51
WISWESSER LINE NOTATION :
T6NJ BN1R DO1&2N1&1 &OV1U1VO

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
42 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - acute pulmonary edema Gastrointestinal - nausea or vomiting
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Cardiac - other changes Vascular - BP elevation not characterized in autonomic section
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
513 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Behavioral - tremor
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
220 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
141 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
23 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
44 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
24400 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8766 gm/kg/90D-C
TOXIC EFFECTS :
Liver - changes in liver weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7378 mg/kg/14D-C
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
91 gm/kg/90D-C
TOXIC EFFECTS :
Cardiac - changes in heart weight Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
77 gm/kg/2Y-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
50 mg/kg
SEX/DURATION :
female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
4200 mg/kg
SEX/DURATION :
female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
420 mg/kg
SEX/DURATION :
female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

MUTATION DATA

TYPE OF TEST :
Mutation in microorganisms
TEST SYSTEM :
Rodent - mouse Lymphocyte
DOSE/DURATION :
400 mg/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 189,285,1987 *** REVIEWS *** TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80498 No. of Facilities: 1580 (estimated) No. of Industries: 3 No. of Occupations: 9 No. of Employees: 6126 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80498 No. of Facilities: 342 (estimated) No. of Industries: 3 No. of Occupations: 13 No. of Employees: 3505 (estimated) No. of Female Employees: 1579 (estimated)
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302-H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xn: Harmful;
Risk Phrases R22;R36/37/38
Safety Phrases S26-S36/37
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS UT1225000
HS Code 2933399090
HS Code 2933399090
Summary 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%